ClinicalTrials.gg
CompletedNCT00796991Updated Jan 6, 2014Results posted

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

A Phase 1 interventional study of Ipilimumab and Carboplatin in Advanced Melanoma, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-06.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing ipilimumab in Melanoma — 21 open to participants now, 42 under way, 5 of them phase 3. Ipilimumab · Melanoma.

Enrollment
50th of 152
72 · median 30
Started
2009
with 5 others
Phase 1
33 of 155
none open now
Registered
21st of 155
by date
Lead sponsor
31 of 155
Bristol-Myers Squibb

Among the 155 studies testing ipilimumab in Melanoma, this one is the 50th largest by enrollment of the 152 interventional ones that give a count, is one of 6 that started in 2009, is one of 33 in phase 1, and was the 21st registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

21 of the 155 studies testing ipilimumab in Melanoma are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing ipilimumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine

03

Conditions studied

  • Advanced Melanoma

Browse trials for

Keywords

  • Untreated Advanced Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic diagnosis of advanced malignant melanoma
  • (ECOG) performances status 0-1
  • Measurable/evaluable disease as per modified World Health Organization (mWHO) criteria

Exclusion criteria

Exclusion Criteria:

  • Evidence of active
  • Prior treatment with anti-cytotoxic lymphocyte antigen 4 () or anti-CD137 (type of tumor necrosis factor) antibody
  • Total greater than (>) 1.5 * (ULN) and (AST) or alanine aminotransferase (ALT) > 2.5 * upper limit of normal (ULN)
  • Prior disease
  • Use of therapies
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    Arm A

    Drug: Ipilimumab · Drug: Carboplatin · Drug: Paclitaxel

  • Active comparator
    Arm B

    Drug: Ipilimumab · Drug: Dacarbazine

  • Active comparator
    Arm C

    Drug: Ipilimumab

Interventions

  • Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks

    Also known as: BMS-734016, MDX-010

  • Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

    Also known as: BMY-26575, PARAPLATIN

  • Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

    Also known as: TAXOL, BMS-181339

  • Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population

    Cmax=micrograms per milliliter (µg/mL): drug concentration versus time for ipilimumab (Day 43) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma by Enzyme-linked Immunosorbent Assay (ELISA); lower level of quantitation (LLOQ)=0.8 µg/mL; upper limit of quantitation (ULOQ)=25.6 µg/mL; Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; from Day 162 on every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined using liquid chromatography tandem mass spectrometry (LC/MS/MS) detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography atmospheric pressure ionization (API) tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

    Time frame: Day 1 (0 h) to Day 43

  2. Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population

    AUC=micrograms\*hour(h) per mL (µg\*h/mL): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

    Time frame: Day 1 (0 h) to Day 43

Secondary outcomes

  1. Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

    Tmax reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..

    Time frame: Day 1 (0 h) to Day 43

  2. Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

    T(HALF) reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

    Time frame: Day 1 (0 h) to Day 43

  3. Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

    CLT reported in milliliters/hour (mL/h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..

    Time frame: Day 1 (0 h) to Day 43

  4. Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

    Vss reported in liters(L): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

    Time frame: Day 1 (0 h) to Day 43

  5. Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants

    Assessments for antitumor activity by physical exam and routine anatomic imaging were at Week 12 and confirmatory imaging at Weeks 16, 20, and 24. Participants with resected index or new lesions were considered progressed in their disease. Complete Response (CR): Complete disappearance of all index lesions; Partial Response (PR): Decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all index lesions, in the absence of Complete Response; Stable Disease (SD): Does not meet criteria for complete or partial response, in the absence of progressive disease. Participants with PR or CR that was not confirmed after at least 4 weeks are scored as SD unless they have new primary lesions; Progressive Disease: At least 25% increase in the sum of products of all index lesions and/or the appearance of any new lesion(s). Unknown=the participants overall response was not known.

    Time frame: Day 1 to Week 48

  6. Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants

    Assessments: Weeks 12, 16, 20, and 24. Participants with resected index or new lesions considered progressed in their disease. The immune-related (ir) response criteria (irRC) represents further modifications of mWHO criteria reflecting clinical experience with ipilimumab in which objective and durable responses (as per mWHO) were observed in participants following progression and without intervening alternative anti-cancer therapy. Immune-related (ir)Complete Response (irCR): Complete disappearance of all index lesions; ir Partial Response (irPR): Decrease, relative to baseline, of 50% or greater in sum of products of the two largest perpendicular diameters of all index and all new measurable lesions, in the absence of irCR; ir Stable Disease (irSD): Does not meet criteria for irCR or irPR, in the absence of progressive disease (PD); ir PD: At least 25% increase in Tumor Burden compared to sum of product diameters (SPD) at nadir. ir Unknown=participants overall response not known.

    Time frame: Day 1 to Week 48

  7. Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants

    Number of participants with an objective response to treatment excluded participants with a best overall response (BOR) of Stable Disease (SD). Disease control is non-progression of disease while on treatment. A participant was considered to have achieved disease control if he/she had a BOR of CR, PR, or SD in the absence of resected index lesions or new lesions while the participant was considered to have an objective response to treatment in he/she had a BOR of CR or PR in the absence of resected index lesions or new lesions.

    Time frame: Day 1 to Week 48

  8. Number of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population

    Adverse events (AEs) and Serious AEs (SAEs) were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events version 3.0. Week 48 database lock was 27 July 2010.

    Time frame: Day 1 to Week 48

  9. Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population

    Absolute lymphocyte counts were obtained from routine hematology panels from 28 days prior to the first treatment with any study medication through the end of the Induction-Dosing Period and were reported as number\*10\^3 cells per micro liter (x10\^3 c/µL).

    Time frame: Day to Week 12

  10. Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population

    Blood pressure was obtained while the participant was sitting down and was measured in millimeters of mercury (mmHg). During the induction phase blood pressure was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Orthostatic blood pressure was to be measured when clinically indicated (for example, participant was experiencing lightheadedness, dizziness, syncope). Blood pressures were recorded at Weeks 1, 4, 7, 10,13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

    Time frame: Day 1 to Week 48

  11. Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population

    Pulse rate was obtained while the participant was sitting down and measured in beats per minute (bpm). During the induction phase pulse rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Pulse rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

    Time frame: Day 1 to Week 48

  12. Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population

    Respiration rate was obtained while the participant was sitting down and measured in breaths per minute (bpm). During the induction phase respiration rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Respiration rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

    Time frame: Day 1 to Week 48

  13. Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population

    Temperature was obtained while the participant was sitting down and was measured in degrees Fahrenheit (F). During the induction phase this vital sign was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Temperature was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

    Time frame: Day 1 to Week 48

  14. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population

    Hemoglobin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 10.0 - less than (\<) lower limit of normal (LLN); GRADE (2): 8.0 - \< 10.0; GRADE (3): 6.5 - \< 8.0; GRADE (4): \< 6.5

    Time frame: Day 1 to Week 48

  15. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population

    Leukocytes are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN; GRADE (2): 2.0 - \< 3.0; GRADE (3): 1.0 - \< 2.0; GRADE (4): \< 1.0.

    Time frame: Day 1 to Week 48

  16. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population

    Lymphocytes (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 0.8 - \< 1.5; GRADE (2): 0.5 - \< 0.8; GRADE (3): 0.2 - \< 0.5; GRADE (4): \< 0.2

    Time frame: Day 1 to Week 48

  17. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population

    Neutrophils (absolute) are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5

    Time frame: Day 1 to Week 48

  18. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population

    Neutrophils plus bands (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5.

    Time frame: Day 1 to Week 48

  19. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population

    Platelets were measured as \*10\^9 cells per liter (c/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 75.0 - \< LLN; GRADE (2): 50.0 - \< 75.0; GRADE (3): 25.0 - \< 50.0; GRADE (4): \< 25.0.

    Time frame: Day 1 to Week 48

  20. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population

    ALT was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.

    Time frame: Day 1 to Week 48

  21. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population

    AST was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.

    Time frame: Day 1 to Week 48

  22. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population

    Albumin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \< LLN - 3.0; GRADE (2): \< 3.0 - 2.0; GRADE (3): \< 2.0 g/dL.

    Time frame: Day 1 to Week 48

  23. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population

    Alkaline Phosphatase was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.

    Time frame: Day 1 to Week 48

  24. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population

    Total Bilirubin was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 3.0 \* ULN; GRADE (3): \> 3.0 - 10.0 \* ULN; GRADE (4): \> 10.0 \* ULN.

    Time frame: Day 1 to Week 48

  25. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population

    Serum potassium was measured as milliequivalents per liter (mEq/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN OR \> ULN - 5.5;; GRADE (2): \> 5.5 - 6.0; GRADE (3): 2.5 - \< 3.0 \> 6.0 - 7.0; GRADE (4): \< 2.5 mEq/L.

    Time frame: Day 1 to Week 48

  26. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population

    Amylase was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 \* ULN.

    Time frame: Day 1 to Week 48

  27. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population

    Total Calcium was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 8.0 - \< LLN OR \> ULN - 11.5; GRADE (2): 7.0 - \< 8.0 \> 11.5 - 12.5; GRADE (3): 6.0 - \< 7.0 \> 12.5 - 13.5; GRADE (4): \< 6.0 \> 13.5 mg/dL.

    Time frame: Day 1 to Week 48

  28. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population

    Total Lipase (as measured with a turbidimetric assay) was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* ULN; GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 X ULN.

    Time frame: Day 1 to Week 48

  29. Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population

    Uric acid was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 \* ULN - 10.0; GRADE (4): \> 10.0 mg/dL.

    Time frame: Day 1 to Week 48

07

Results

Posted Jan 6, 2014

Participant flow

17 February 2009 study initiated; last patient, last visit (LPLV) 30 October 2012.

Participant flow — Overall Study
MilestonePaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Started201920
Completed576
Not completed151214
Withdrew: Adverse event001
Withdrew: Death200
Withdrew: Disease progression1097
Withdrew: Study drug toxicity335
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population

Cmax=micrograms per milliliter (µg/mL): drug concentration versus time for ipilimumab (Day 43) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma by Enzyme-linked Immunosorbent Assay (ELISA); lower level of quantitation (LLOQ)=0.8 µg/mL; upper limit of quantitation (ULOQ)=25.6 µg/mL; Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; from Day 162 on every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined using liquid chromatography tandem mass spectrometry (LC/MS/MS) detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography atmospheric pressure ionization (API) tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

Time frame:
Day 1 (0 h) to Day 43
Reported as:
Geometric mean · µg/mL
Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population
µg/mLPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Cmax of Ipilimumab N=14, 14, 12234.54 ± 29246.50 ± 35251.05 ± 34
Cmax of Paclitaxel (Day 1) N=20, 0, 03.35 ± 23NA ± NANA ± NA
Cmax of Paclitaxel (Day 43) N=14, 0, 03.19 ± 26NA ± NANA ± NA
Cmax of Dacarbazine (Day 1) N=0, 19, 0NA ± NA18.23 ± 37NA ± NA
Cmax of Dacarbazine (Day 43) N=0, 16, 0NA ± NA18.61 ± 30NA ± NA
Cmax of AIC (Day 1) N=0, 19, 0NA ± NA3.57 ± 36NA ± NA
Cmax of AIC (Day 43) N=0, 17, 0NA ± NA3.98 ± 40NA ± NA
Statistical analysis
  • Paclitaxel, Carboplatin, Ipilimumab · Mixed Models Analysis · Adjusted geometric mean ratio: 0.963 · 90% CI 0.794 to 1.168A general linear mixed model was applied to paclitaxel log(Cmax) using study day as a fixed effect.
  • Dacarbazine, Ipilimumab · Mixed Models Analysis · Adjusted geometric mean ratio: 1.027 · 90% CI 0.848 to 1.243study day was used as a fixed effect
  • Dacarbazine, Ipilimumab · Mixed Models Analysis · Adjusted geometric mean ratio: 1.058 · 90% CI 0.974 to 1.150study day was used as a fixed effect
  • Paclitaxel, Carboplatin, Ipilimumab vs Ipilimumab · linear model · Adjusted geometric mean ratio: 0.934 · 90% CI 0.768 to 1.136treatment arm as a fixed effect
  • Dacarbazine, Ipilimumab vs Ipilimumab · linear model · Adjusted geometric mean ratio: 0.982 · 90% CI 0.798 to 1.208treatment arm as a fixed effect
SecondaryPharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

Tmax reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..

Time frame:
Day 1 (0 h) to Day 43
Reported as:
Median · h
Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
hPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Tmax of Ipilimumab N=14, 14, 121.51 (1.5 to 24.0)4.00 (1.5 to 24.6)1.56 (1.5 to 4.0)
Tmax of Paclitaxel (Day 1) N=20, 0, 03.00 (2.9 to 4.3)NA (NA to NA)NA (NA to NA)
Tmax of Paclitaxel (Day 43) N=14, 0, 03.00 (1.5 to 9.5)NA (NA to NA)NA (NA to NA)
Tmax of Dacarbazine (Day 1) N=0, 18, 0NA (NA to NA)1.00 (1.0 to 2.8)NA (NA to NA)
Tmax of Dacarbazine (Day 43) N=0, 15, 0NA (NA to NA)1.00 (1.0 to 1.1)NA (NA to NA)
Tmax of AIC (Day 1) N=0, 19 0NA (NA to NA)1.00 (1.0 to 2.8)NA (NA to NA)
Tmax of AIC (Day 43) N=0, 16, 0NA (NA to NA)1.00 (1.0 to 2.5)NA (NA to NA)
SecondaryPharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

T(HALF) reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

Time frame:
Day 1 (0 h) to Day 43
Reported as:
Mean · h
Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
hPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
T(HALF) of Ipilimumab N=14, 14, 1213.93 ± 7.5413.39 ± 4.5115.25 ± 4.64
T(HALF) of Paclitaxel (Day 1) N=20, 0, 010.26 ± 1.57NA ± NANA ± NA
T(HALF) of Paclitaxel (Day 43) N=14, 0, 010.41 ± 2.73NA ± NANA ± NA
T(HALF) of Dacarbazine (Day 1) N=0, 19, 0NA ± NA2.11 ± 0.87NA ± NA
T(HALF) of Dacarbazine (Day 43) N=0, 16, 0NA ± NA2.07 ± 0.85NA ± NA
T(HALF) of AIC (Day 1) N=0, 18, 0NA ± NA2.24 ± 0.96NA ± NA
T(HALF) of AIC (Day 43) N=0, 16, 0NA ± NA2.21 ± 0.81NA ± NA
SecondaryPharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

CLT reported in milliliters/hour (mL/h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..

Time frame:
Day 1 (0 h) to Day 43
Reported as:
Geometric mean · mL/h
Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
mL/hPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
CLT of Ipilimumab N=14, 14, 1211.63 ± 5011.17 ± 3410.23 ± 44
CLT of Paclitaxel (Day 1) N=20, 0, 027.87 ± 28NA ± NANA ± NA
CLT of Paclitaxel (Day 43) N=14, 0, 025.44 ± 26NA ± NANA ± NA
CLT of Dacarbazine (Day 1) N=0, 19, 0NA ± NA34.33 ± 52NA ± NA
CLT of Dacarbazine (Day 43) N=0, 16, 0NA ± NA37.09 ± 49NA ± NA
CLT of AIC (Day 1) N=0, 19, 0NA ± NA91.67 ± 28NA ± NA
CLT of AIC (Day 43) N=0, 17, 0NA ± NA88.75 ± 37NA ± NA
PrimaryArea Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population

AUC=micrograms\*hour(h) per mL (µg\*h/mL): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

Time frame:
Day 1 (0 h) to Day 43
Reported as:
Geometric mean · µg*h/mL
Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population
µg*h/mLPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
AUC(0-21d) of Ipilimumab N=14, 14, 1246925.36 ± 3649569.06 ± 2554039.79 ± 28
AUC(INF) of Paclitaxel (Day 1) N=20, 0, 012.37 ± 24NA ± NANA ± NA
AUC(INF) of Paclitaxel (Day 43) N=14, 0, 013.41 ± 24NA ± NANA ± NA
AUC(INF) of Dacarbazine (Day 1) N=0, 19, 0NA ± NA47.36 ± 68NA ± NA
AUC(INF) of Dacarbazine (Day 43) N=0, 16, 0NA ± NA41.13 ± 55NA ± NA
AUC(INF) of AIC (Day 1) N=0, 18, 0NA ± NA17.68 ± 26NA ± NA
AUC(INF) of AIC (Day 43) N=0, 16, 0NA ± NA17.38 ± 36NA ± NA
Statistical analysis
  • Paclitaxel, Carboplatin, Ipilimumab · Mixed Models Analysis · Geometric mean ratio: 1.068 · 90% CI 0.954 to 1.196A general linear mixed model was applied to paclitaxel log\[AUC(INF)\] using study day as a fixed effect.
  • Dacarbazine, Ipilimumab · Mixed Models Analysis · Adjusted geometric mean ratio: 0.912 · 90% CI 0.757 to 1.099A general linear mixed model was applied to dacarbazine log\[AUC(INF)\] using study day as a fixed effect.
  • Dacarbazine, Ipilimumab · Mixed Models Analysis · Adjusted geometric mean ratio: 0.970 · 90% CI 0.891 to 1.056A general linear mixed model was applied to active metabolite AIC log\[AUC(INF)\] using study day as a fixed effect.
  • Paclitaxel, Carboplatin, Ipilimumab vs Ipilimumab · linear model · Adjusted geometric mean ratio: 0.934 · 90% CI 0.768 to 1.136treatment arm as fixed effect
  • Dacarbazine, Ipilimumab vs Ipilimumab · linear model · Adjusted geometric mean ratio: 0.982 · 90% CI 0.7981 to 1.208treatment arm as a fixed effect
SecondaryPharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population

Vss reported in liters(L): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.

Time frame:
Day 1 (0 h) to Day 43
Reported as:
Geometric mean · L
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
LPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Vss of Ipilimumab N=14, 14, 125.10 ± 254.88 ± 215.05 ± 29
Vss of Paclitaxel (Day 43) N=14, 0, 0205.63 ± 31NA ± NANA ± NA
Vss of Dacarbazine (Day 43) N=0, 16, 0NA ± NA107.90 ± 31NA ± NA
Vss of AIC (Day 1) N=0, 17, 0NA ± NA342.64 ± 47NA ± NA
SecondaryNumber of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants

Assessments for antitumor activity by physical exam and routine anatomic imaging were at Week 12 and confirmatory imaging at Weeks 16, 20, and 24. Participants with resected index or new lesions were considered progressed in their disease. Complete Response (CR): Complete disappearance of all index lesions; Partial Response (PR): Decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all index lesions, in the absence of Complete Response; Stable Disease (SD): Does not meet criteria for complete or partial response, in the absence of progressive disease. Participants with PR or CR that was not confirmed after at least 4 weeks are scored as SD unless they have new primary lesions; Progressive Disease: At least 25% increase in the sum of products of all index lesions and/or the appearance of any new lesion(s). Unknown=the participants overall response was not known.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Complete Response110
Partial Response145
Stable Disease654
Progressive Disease988
Unknown313
SecondaryNumber of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants

Assessments: Weeks 12, 16, 20, and 24. Participants with resected index or new lesions considered progressed in their disease. The immune-related (ir) response criteria (irRC) represents further modifications of mWHO criteria reflecting clinical experience with ipilimumab in which objective and durable responses (as per mWHO) were observed in participants following progression and without intervening alternative anti-cancer therapy. Immune-related (ir)Complete Response (irCR): Complete disappearance of all index lesions; ir Partial Response (irPR): Decrease, relative to baseline, of 50% or greater in sum of products of the two largest perpendicular diameters of all index and all new measurable lesions, in the absence of irCR; ir Stable Disease (irSD): Does not meet criteria for irCR or irPR, in the absence of progressive disease (PD); ir PD: At least 25% increase in Tumor Burden compared to sum of product diameters (SPD) at nadir. ir Unknown=participants overall response not known.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
ir Complete Response110
ir Partial Response455
ir Stable Disease556
ir Progressive Disease776
ir Unknown313
SecondaryNumber of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants

Number of participants with an objective response to treatment excluded participants with a best overall response (BOR) of Stable Disease (SD). Disease control is non-progression of disease while on treatment. A participant was considered to have achieved disease control if he/she had a BOR of CR, PR, or SD in the absence of resected index lesions or new lesions while the participant was considered to have an objective response to treatment in he/she had a BOR of CR or PR in the absence of resected index lesions or new lesions.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Participants with Objective Response255
Participants with Disease Control8109
SecondaryNumber of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population

Adverse events (AEs) and Serious AEs (SAEs) were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events version 3.0. Week 48 database lock was 27 July 2010.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Participants with AEs201920
Participants with SAEs989
Participants with SAEs Treatment-Related465
Deaths1257
Deaths Treatment-Related000
Participants discontinued due to AE(s)675
SecondaryMean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population

Absolute lymphocyte counts were obtained from routine hematology panels from 28 days prior to the first treatment with any study medication through the end of the Induction-Dosing Period and were reported as number\*10\^3 cells per micro liter (x10\^3 c/µL).

Time frame:
Day to Week 12
Reported as:
Mean · 10^3 cells/µL
Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population
10^3 cells/µLPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Nominal Ipilimumab Induction Dose Number 11.19 (0.79 to 1.59)1.41 (1.00 to 1.82)1.28 (0.91 to 1.64)
Nominal Ipilimumab Induction Dose Number 21.62 (1.27 to 1.98)2.05 (1.69 to 2.42)1.56 (1.18 to 1.93)
Nominal Ipilimumab Induction Dose Number 31.43 (1.06 to 1.80)1.96 (1.59 to 2.33)1.99 (1.59 to 2.39)
Nominal Ipilimumab Induction Dose Number 41.42 (1.03 to 1.80)1.87 (1.49 to 2.25)1.80 (1.39 to 2.22)
End of Ipilimumab Induction dosing Period1.67 (1.23 to 2.10)2.07 (1.63 to 2.51)1.73 (1.20 to 2.25)
Statistical analysis
  • Paclitaxel, Carboplatin, Ipilimumab vs Dacarbazine, Ipilimumab vs Ipilimumab · conditional F test · p = 0.027 (p-value was not corrected for multiple testing. F-statistic = 1.86.)15 degrees freedom (DF) in numerator and 335 DF in denominator.
  • Paclitaxel, Carboplatin, Ipilimumab vs Dacarbazine, Ipilimumab vs Ipilimumab · Omnibus conditional F-test · p = 0.5 (P-values were not corrected for multiple testing. F Statistic =0.94)10 Degrees Freedom (DF) in numerator and 335 DF in denominator.
  • Paclitaxel, Carboplatin, Ipilimumab vs Ipilimumab · conditional F-test · p = 0.37 (P-values were not corrected for multiple testing. F Statistic =1.08)5 Degrees Freedom (DF) in numerator and 335 DF in denominator.
  • Paclitaxel, Carboplatin, Ipilimumab vs Dacarbazine, Ipilimumab · conditional F-test · p = 0.85 (P-values were not corrected for multiple testing. F Statistic =0.39)5 Degrees Freedom (DF) in numerator and 335 DF in denominator.
  • Dacarbazine, Ipilimumab vs Ipilimumab · conditional F-test · p = 0.22 (P-values were not corrected for multiple testing. F Statistic = 1.41)5 Degrees Freedom (DF) in numerator and 335 DF in denominator.
SecondaryMean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population

Blood pressure was obtained while the participant was sitting down and was measured in millimeters of mercury (mmHg). During the induction phase blood pressure was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Orthostatic blood pressure was to be measured when clinically indicated (for example, participant was experiencing lightheadedness, dizziness, syncope). Blood pressures were recorded at Weeks 1, 4, 7, 10,13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

Time frame:
Day 1 to Week 48
Reported as:
Mean · mmHg
Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population
mmHgPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Diastolic Blood Pressure at Week 16 (N=1, 6, 9)10.0 ± NA6.6 ± 11.34.9 ± 13.3
Diastolic Blood Pressure at Week 48 (N=1, 4, 4)2.0 ± NA7.0 ± 11.38.5 ± 8.2
Systolic Blood Pressure at Week 16 (N=1, 6, 9)22.0 ± NA2.7 ± 12.29.7 ± 14.1
Systolic Blood Pressure at Week 48 (N=1, 4, 4)5.0 ± NA1.0 ± 17.112.0 ± 8.6
SecondaryMean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population

Pulse rate was obtained while the participant was sitting down and measured in beats per minute (bpm). During the induction phase pulse rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Pulse rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

Time frame:
Day 1 to Week 48
Reported as:
Mean · bpm
Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population
bpmPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Pulse Rate at Week 16 (N=1, 6, 9)24.0 ± NA0.3 ± 13.9-0.7 ± 15.9
Pulse Rate at Week 48 (N=1, 4, 4)-3.0 ± NA-9.5 ± 13.67.5 ± 10.3
SecondaryMean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population

Respiration rate was obtained while the participant was sitting down and measured in breaths per minute (bpm). During the induction phase respiration rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Respiration rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

Time frame:
Day 1 to Week 48
Reported as:
Mean · bpm
Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population
bpmPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Respiration Rate at Week 16 (N=1, 5, 6)0 ± NA1.4 ± 2.4-0.8 ± 2.2
Respiration Rate at Week 48 (N=1, 3, 3)-2.0 ± NA-2.7 ± 1.2-1.3 ± 1.2
SecondaryMean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population

Temperature was obtained while the participant was sitting down and was measured in degrees Fahrenheit (F). During the induction phase this vital sign was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Temperature was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.

Time frame:
Day 1 to Week 48
Reported as:
Mean · degrees F
Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population
degrees FPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Temperature at Week 16 (N=1, 6, 9)-0.5 ± NA-0.1 ± 0.80.2 ± 0.9
Temperature at Week 48 (N=1, 4, 4)0.4 ± NA0.0 ± 0.7-0.2 ± 0.7
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population

Hemoglobin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 10.0 - less than (\<) lower limit of normal (LLN); GRADE (2): 8.0 - \< 10.0; GRADE (3): 6.5 - \< 8.0; GRADE (4): \< 6.5

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Hemoglobin Grade 0345
Hemoglobin Grade 191310
Hemoglobin Grade 2814
Hemoglobin Grade 3010
Hemoglobin Not Reported001
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population

Leukocytes are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN; GRADE (2): 2.0 - \< 3.0; GRADE (3): 1.0 - \< 2.0; GRADE (4): \< 1.0.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Leukocytes Grade 081317
Leukocytes Grade 1441
Leukocytes Grade 2221
Leukocytes Grade 3500
Leukocytes Grade 4100
Leukocytes Not Reported001
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population

Lymphocytes (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 0.8 - \< 1.5; GRADE (2): 0.5 - \< 0.8; GRADE (3): 0.2 - \< 0.5; GRADE (4): \< 0.2

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Lymphocytes Grade 0456
Lymphocytes Grade 1121311
Lymphocytes Grade 2313
Lymphocytes Grade 3100
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population

Neutrophils (absolute) are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Neutrophils Grade 0201819
Neutrophils Grade 1001
Neutrophils Grade 3010
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population

Neutrophils plus bands (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Neutrophils Plus Bands Grade 0201819
Neutrophils Plus Bands Grade 1001
Neutrophils Plus Bands Grade 3010
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population

Platelets were measured as \*10\^9 cells per liter (c/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 75.0 - \< LLN; GRADE (2): 50.0 - \< 75.0; GRADE (3): 25.0 - \< 50.0; GRADE (4): \< 25.0.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Platelet Count Grade 0201918
Platelet Count Grade 1002
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population

ALT was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
ALT Grade 0181816
ALT Grade 1213
ALT Grade 2001
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population

AST was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
AST Grade 0181815
AST Grade 1214
AST Grade 2001
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population

Albumin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \< LLN - 3.0; GRADE (2): \< 3.0 - 2.0; GRADE (3): \< 2.0 g/dL.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Albumin Grade 0171414
Albumin Grade 1356
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population

Alkaline Phosphatase was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Alkaline Phosphatase Grade 0141818
Alkaline Phosphatase Grade 1610
Alkaline Phosphatase Grade 2002
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population

Total Bilirubin was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 3.0 \* ULN; GRADE (3): \> 3.0 - 10.0 \* ULN; GRADE (4): \> 10.0 \* ULN.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Total Bilirubin Grade 0201718
Total Bilirubin Grade 1012
Total Bilirubin Grade 2010
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population

Serum potassium was measured as milliequivalents per liter (mEq/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN OR \> ULN - 5.5;; GRADE (2): \> 5.5 - 6.0; GRADE (3): 2.5 - \< 3.0 \> 6.0 - 7.0; GRADE (4): \< 2.5 mEq/L.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Serum Potassium (High) Grade 0201717
Serum Potassium (High) Grade 1021
Serum Potassium (High) Grade 2002
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population

Amylase was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 \* ULN.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Total Amylase Grade 0201916
Total Amylase Grade 1002
Total Amylase Grade 2001
Total Amylase Grade 3001
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population

Total Calcium was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 8.0 - \< LLN OR \> ULN - 11.5; GRADE (2): 7.0 - \< 8.0 \> 11.5 - 12.5; GRADE (3): 6.0 - \< 7.0 \> 12.5 - 13.5; GRADE (4): \< 6.0 \> 13.5 mg/dL.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Total Calcium (High) Grade 0181919
Total Calcium (High) Grade 1201
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population

Total Lipase (as measured with a turbidimetric assay) was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* ULN; GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 X ULN.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Total Lipase Grade 01264
Total Lipase Grade 1100
Total Lipase Grade 4001
Total Lipase Not Reported71315
SecondaryNumber of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population

Uric acid was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 \* ULN - 10.0; GRADE (4): \> 10.0 mg/dL.

Time frame:
Day 1 to Week 48
Reported as:
Number · participants
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population
participantsPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Uric Acid Grade 0201917
Uric Acid Grade 1013

Adverse events

Collected over Day 1 up to last patient last visit (LPLV) 30 October 2012. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel, Carboplatin, Ipilimumab—12/20 (60%)20/20 (100%)
Dacarbazine, Ipilimumab—10/19 (52.6%)19/19 (100%)
Ipilimumab—14/20 (70%)20/20 (100%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/201/192/20
Abdominal painGastrointestinal disorders0/204/191/20
DyspnoeaRespiratory, thoracic and mediastinal disorders4/201/190/20
DiarrhoeaGastrointestinal disorders1/201/193/20
PyrexiaGeneral disorders3/201/191/20
HypotensionVascular disorders0/202/191/20
Autoimmune hepatitisHepatobiliary disorders1/202/190/20
Pleural effusionRespiratory, thoracic and mediastinal disorders2/200/190/20
FatigueGeneral disorders2/200/190/20
Mental status changesPsychiatric disorders0/200/192/20
Most frequent other events
Showing 10 of 260
Most frequent other events
EventPaclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumab
FatigueGeneral disorders12/2018/1912/20
RashSkin and subcutaneous tissue disorders16/2011/1917/20
NauseaGastrointestinal disorders12/2015/197/20
PruritusSkin and subcutaneous tissue disorders13/2014/1915/20
DiarrhoeaGastrointestinal disorders10/2012/1912/20
AlopeciaSkin and subcutaneous tissue disorders12/201/193/20
HyperglycaemiaMetabolism and nutrition disorders12/206/195/20
Haemoglobin decreasedInvestigations11/207/194/20
Aspartate aminotransferase increasedInvestigations5/2010/193/20
HeadacheNervous system disorders7/2010/196/20

Baseline characteristics

All randomized and treated participants

Age, Categorical
Age, Categorical(Participants)Paclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumabTotal
<=18 years0000
Between 18 and 65 years15121239
>=65 years57820
Age, Continuous
Age, Continuous(years)Paclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumabTotal
Mean55 ± 1454 ± 1760 ± 1157 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumabTotal
Female76821
Male13131238
Region of Enrollment
Region of Enrollment(participants)Paclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumabTotal
United States20192059
Eastern Cooperative Oncology Group (ECOG)
Eastern Cooperative Oncology Group (ECOG)(participants)Paclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumabTotal
014171647
161411
20000
Not Reported0101
Number of Target Lesions
Number of Target Lesions(Participants)Paclitaxel, Carboplatin, IpilimumabDacarbazine, IpilimumabIpilimumabTotal
1 lesion43411
2 lesions3306
3 lesions34411
4 lesions0257
>=5 lesions107724
08

Study locations

4 sites
  • The Angeles Clinic & Research Inst.
    Los Angeles, California 90025, United States
  • H Lee Moffit Cancer Cnt And Res Inst
    Tampa, Florida 33612, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Blumenthal Cancer Center, Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Nov 2009 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2008
First posted
Nov 24, 2008
Start
Feb 2009
Primary completionActual
Nov 2009
CompletionActual
Oct 2012
Results first posted
Jan 6, 2014
Last update
Jan 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00796991
Collaborators
Medarex
Responsible party
Sponsor
First posted
Nov 24, 2008
Start date
Feb 2009
Primary completion
Nov 2009
Completion
Oct 2012
Results posted
Jan 6, 2014
Last update
Jan 6, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Carboplatin · Paclitaxel · Dacarbazine

Start the discussion